Furthermore, as mentioned in the introduction and outlined in more detail in the following section, IDH mutations have been recognized as key molecular markers of certain gliomas that distinguish them from other, more malignant forms, so that their non-invasive detection could facilitate glioma classification and therapy planning in affected patients. The gene discussed is IDH2; the disease is glioma.